NZ602954A - Inhibitors of protein tyrosine kinase activity - Google Patents

Inhibitors of protein tyrosine kinase activity

Info

Publication number
NZ602954A
NZ602954A NZ602954A NZ60295411A NZ602954A NZ 602954 A NZ602954 A NZ 602954A NZ 602954 A NZ602954 A NZ 602954A NZ 60295411 A NZ60295411 A NZ 60295411A NZ 602954 A NZ602954 A NZ 602954A
Authority
NZ
New Zealand
Prior art keywords
pyridin
compounds
thieno
tyrosine kinase
protein tyrosine
Prior art date
Application number
NZ602954A
Other languages
English (en)
Inventor
Franck Raeppel
Yohei Yuki
Lijie Zhan
Frederic Gaudette
Norifumi Sato
Arkadii Vaisburg
Michael Mannion
Stephane Raeppel
Stephen William Claridge
Masashi Kishida
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of NZ602954A publication Critical patent/NZ602954A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ602954A 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity NZ602954A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
PCT/CA2011/000394 WO2011127567A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
NZ602954A true NZ602954A (en) 2014-11-28

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ602954A NZ602954A (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity
NZ602948A NZ602948A (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ602948A NZ602948A (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Country Status (19)

Country Link
US (3) US8906852B2 (enExample)
EP (2) EP2563794A4 (enExample)
JP (2) JP2013523846A (enExample)
KR (2) KR20130058006A (enExample)
CN (2) CN102947315A (enExample)
AR (2) AR080871A1 (enExample)
AU (2) AU2011241422B2 (enExample)
CA (2) CA2796008A1 (enExample)
CO (2) CO6640224A2 (enExample)
EA (2) EA201291052A1 (enExample)
MX (2) MX2012012031A (enExample)
MY (1) MY157319A (enExample)
NZ (2) NZ602954A (enExample)
PH (2) PH12012502070A1 (enExample)
SG (2) SG184883A1 (enExample)
TW (2) TW201204735A (enExample)
UA (1) UA108878C2 (enExample)
WO (2) WO2011127567A1 (enExample)
ZA (2) ZA201207482B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
MX2010009729A (es) * 2008-03-05 2010-12-21 Methylgene Inc Inhibidores de actividad de proteina tirosina quinasa.
MX2012012031A (es) * 2010-04-16 2012-12-17 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
US20130090327A1 (en) * 2011-09-30 2013-04-11 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
EP3200589B1 (en) 2014-09-10 2026-03-11 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
CN121108077A (zh) * 2025-09-02 2025-12-12 领泰生物医药(绍兴)有限公司 一种含氮杂环化合物的制备方法及其中间体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
EP1781664B1 (en) * 2004-07-30 2013-09-04 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
MX2007014617A (es) * 2005-05-20 2008-02-11 Methylgene Inc Inhibidores de senalizacion de receptor de factor de crecimiento endotelial bascular y receptor de factor de crecimiento de hepatocitos.
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
MX2010009729A (es) * 2008-03-05 2010-12-21 Methylgene Inc Inhibidores de actividad de proteina tirosina quinasa.
MX2012012031A (es) * 2010-04-16 2012-12-17 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
AU2011241422A1 (en) 2012-11-01
US20110257100A1 (en) 2011-10-20
KR20130058006A (ko) 2013-06-03
JP2013525286A (ja) 2013-06-20
MX2012012032A (es) 2012-12-17
AR080875A1 (es) 2012-05-16
US8455484B2 (en) 2013-06-04
AR080871A1 (es) 2012-05-16
UA108878C2 (ru) 2015-06-25
US20110257175A1 (en) 2011-10-20
CA2796008A1 (en) 2011-10-20
EP2563794A1 (en) 2013-03-06
PH12012502073A1 (en) 2013-02-11
AU2011241420B2 (en) 2015-04-16
SG184883A1 (en) 2012-11-29
AU2011241422B2 (en) 2015-05-07
CN102947315A (zh) 2013-02-27
WO2011127567A1 (en) 2011-10-20
ZA201207482B (en) 2013-09-25
US20140315801A1 (en) 2014-10-23
NZ602948A (en) 2014-09-26
EP2563795A1 (en) 2013-03-06
JP2013523846A (ja) 2013-06-17
EP2563794A4 (en) 2013-12-04
CA2796054A1 (en) 2011-10-20
KR20130100234A (ko) 2013-09-10
MY157319A (en) 2016-05-31
MX2012012031A (es) 2012-12-17
WO2011127565A1 (en) 2011-10-20
US8906852B2 (en) 2014-12-09
CN103025740A (zh) 2013-04-03
ZA201207557B (en) 2013-06-26
CO6630193A2 (es) 2013-03-01
TW201204734A (en) 2012-02-01
PH12012502070A1 (en) 2015-05-08
EA201291052A1 (ru) 2013-04-30
CN103025740B (zh) 2015-07-01
SG184882A1 (en) 2012-11-29
TW201204735A (en) 2012-02-01
EP2563795A4 (en) 2013-10-23
CO6640224A2 (es) 2013-03-22
EA201291055A1 (ru) 2013-09-30

Similar Documents

Publication Publication Date Title
NZ602948A (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
PH12020500485A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
NZ610230A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
WO2013012915A9 (en) Heterocyclic compounds and uses thereof
PH12014501504A1 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
PE20160540A1 (es) Inhibidores de bromodominios
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
HK1199725A1 (en) Heterocyclic compounds and uses thereof
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
MY156536A (en) Inhibitors of protein tyrosine kinase activity
PH12013502059A1 (en) Pyrrolotriazinone derivatives as p13k inhibitors
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
WO2014033447A3 (en) Diaryl urea derivatives as p38 map kinase inhibitors
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
MX339302B (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20130640A1 (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
HK1210162A1 (en) Pyrimidinone derivatives as antimalarial agents
NZ712030A (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
MX2012001529A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.
CO2017002266A2 (es) Derivados de 5-[3-metil-2-[(4-metillsulfonilpiperazin-1-il)metil]-7-morfolinotieno [2,3-c] piridinil como inhibidores de la quinasa pi3
IL196469A (en) History of triazine and their use in the preparation of drugs for the treatment of diseases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 APR 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20150611

LAPS Patent lapsed